PATENT CLAIM ANALYSIS

Application Number: 16162239
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["514", "001000"]

Abstract:
The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.

Claim (Index 16):
The method of  claim 14 , wherein\n the one or more Rhes-disrupting agents comprises an agent which reduces Rhes protein abundance in a cell.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 1.54098
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14004615', '15397569', '15207836', '15503636', '15905748']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7368093157754427
- 35 USC 102 Novelty (BERT): 0.4957963597495861
- Combined Prediction Score: 0.7127080201728571
- Mean Citation Score: 168.65639399999995
- Max Citation Score: 179.88133
- Similarity Product: 114.76100973916888

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test